
Opinion|Videos|October 7, 2024
Reflections on Plozasiran Trial Data and Future Potential
Key Takeaways
- Gene therapies, antisense oligonucleotides, and RNA interference technologies are promising approaches for FCS treatment, focusing on triglyceride reduction and symptom management.
- Clinicians should engage in continuous education, attend conferences, and collaborate with specialists to integrate emerging therapies into practice.
Panelists discuss how various new and developing approaches for treating familial chylomicronemia syndrome are emerging, and emphasize the importance for clinicians to integrate these advancements into practice while staying current with ongoing research and evolving treatment strategies.
Advertisement
Video content above is prompted by the following:
What other approaches have been tested or are in development for treating familial chylomicronemia syndrome (FCS)?
How can clinicians integrate emerging therapy advancements into their clinical practice for the management of FCS? What strategies should be adopted to stay updated with ongoing research and treatment options?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on HCPLive
1
Kidney Compass: VISIONARY 2-Year eGFR Data in IgA Nephropathy
2
Bimekizumab Data Support Case for Earlier Intervention in HS
3
Rethinking HFpEF Screening and Care, With Ronald D'Agostino, DO
4
Q&A: Anaphylaxis Recognition and Epinephrine Use, With Jay Lieberman, MD
5



































































